Coronavirus (COVID-19) Update: FDA Authorizes First Oral Antiviral for Treatment of COVID-19

Dec 22. 2021 – Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for Pfizer’s Paxlovid (nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use) for the treatment of mild-to-moderate coronavirus disease (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kilograms or about 88 pounds) with positive results of direct SARS-CoV-2 testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death. Paxlovid is available by prescription only and should be initiated as soon as possible after diagnosis of COVID-19 and within five days of symptom onset. Continue reading

The MedTech Conference Plans to Return to Boston in 2022 with a Strong In-Person Presence

WASHINGTON, D.C. – The MedTech Conference, powered by the Advanced Medical Technology Association (AdvaMed), announced today it will return to Boston from October 24-26, 2022, with hopes of reconvening the industry after two unconventional years. The annual three-day event provides world-class programming, networking, and business development opportunities for the global medical technology community. The conference will once again offer options for virtual attendance while encouraging safe in-person participation.

Continue reading

Scintillation Nanotechnologies, Inc. to exhibit nanoparticle scintillator platform at SLAS 2022 International Conference and Exhibition.

Tucson-based Scintillation Nanotechnologies, Inc. has been selected by the Society for Laboratory Automation and Screening (SLAS) to be included on “Innovation AveNEW” at the society’s upcoming 2022 International Conference and Exhibition. The company – a startup founded to commercialize inventions stemming from research at the University of Arizona – has developed next generation nanoparticles for the detection of radiolabeled compounds directly in aqueous samples, eliminating the need for extensive sample preparation and sample destruction that are experienced with competing products.  The unique chemical and physical properties of the company’s aquaSCINTTM and nanoSPATM products give researchers unprecedented insight into drug uptake, binding, and distribution while saving time and reducing costly hazardous waste . Continue reading